Cvs Health (CVS) EBITDA (2009 - 2026)

Cvs Health's EBITDA history runs 18 years deep, the most recent figure standing at $4.7 billion for Q1 2026.

• Quarterly EBITDA rose 800.0% year-over-year to $4.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (down 77.82% YoY) and the FY2025 annual result came in at $2.2 billion, down 73.78% from the prior year.
• EBITDA was $4.7 billion for Q1 2026 at Cvs Health, up from $594.0 million in the prior quarter.
• Across five years, EBITDA topped out at $7.1 billion in Q4 2024 and bottomed at -$3.9 billion in Q3 2022.
• A 5-year average of $1.6 billion and a median of $594.0 million in 2025 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA plunged 1693.09% — and 2024, when it soared 2555.97%.
• Cvs Health's EBITDA stood at $3.7 billion in 2022, then slumped by 92.68% to $268.0 million in 2023, then surged by 2555.97% to $7.1 billion in 2024, then sank by 91.65% to $594.0 million in 2025, then surged by 687.88% to $4.7 billion in 2026.
• Business Quant data shows CVS's EBITDA at $4.7 billion in Q1 2026, $594.0 million in Q4 2025, and -$3.2 billion in Q3 2025.